Lv1
84 积分 2024-07-02 加入
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
17小时前
待确认
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
17天前
已完结
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
18天前
已完结
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences
18天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
24天前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
1个月前
已完结
Targeting immune cell circuits and trafficking in inflammatory bowel disease
1个月前
已完结
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
1个月前
已完结
IRF4 in multiple myeloma—Biology, disease and therapeutic target
1个月前
已完结
Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
1个月前
已关闭
皖公网安备34019202002308
